ZBIO
Zenas BioPharma, Inc. (ZBIO) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Revenue base remains extremely small at $0.016 per share, limiting scale despite a large market cap.
No recent news indicates a new commercial catalyst or demand inflection.
Profitability
Margins remain deeply negative, with gross margin at -59.7% and net margin at -484.4%.
Returns on capital are still severely negative, with ROIC at -74.7% and ROE at -189.7%.
Financial Strength
Liquidity is strong with a current ratio of 9.9x and cash ratio of 3.0x.
Leverage is manageable, with debt-to-equity at 0.91x and net debt to EBITDA near zero.
Valuation
Valuation remains extremely stretched on sales, with EV/Sales at 2000.1x and P/S at 1972.9x.
Negative free cash flow and negative earnings keep traditional valuation support weak.
Execution Risk
Operating cash flow remains negative and the cash conversion cycle is long at 246 days.
High R&D and SG&A intensity relative to revenue continue to pressure operating leverage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

